-
Jiangsu: Psychological treatment programs have been included in basic medical insurance since October
Time of Update: 2022-09-21
The reporter learned from the recent meeting of the Jiangsu Provincial People's Congress Standing Committee on the key handling of the deputies' suggestions on medical security that the Jiangsu Provi
-
The chain rate continues to increase, and a large number of single pharmacies will disappear!
Time of Update: 2022-09-21
Among them, according to the high-quality development construction goal of "retail chain rate of nearly 70%" in 2025, with 606,500 pharmacies as the base, the number of stores of single pharmacies will be reduced to about 180,000 in the next three years, compared with about 250,000 now, or a sharp decrease of about 70,000.
-
With the development of the API business, a large number of pharmaceutical companies are accelerating their expansion and transformation and upgrading
Time of Update: 2022-09-21
Among them, it is worth mentioning that despite the impact of the global epidemic and the intensification of api price competition, in the first half of this year, Huahai Pharmaceutical's API and intermediate business achieved sales revenue of 1.
-
Under the change of the pharmaceutical environment, a large number of multinational pharmaceutical companies will accelerate the "change of coach" in 2022!
Time of Update: 2022-09-21
AstraZeneca: Ming Liu takes over as Vice President of AstraZeneca China AstraZeneca: Ming Liu takes over as Vice President of AstraZeneca China On August 30, AstraZeneca announced the appointment of Liu Ming as Vice President of AstraZeneca China, head of the Lung Cancer Treatment and Tumor Immunotherapy Related Areas of the Oncology Division, and joined the China management team to report directly to Chen Kangwei, General Manager of AstraZeneca Oncology Division, effective August 30.
-
Sinopharm's performance reached a new high Sinopharm Shares, Tai Chi... Strategic layout exposure
Time of Update: 2022-09-21
On September 6, the list of the top 500 Chinese enterprises in 2022 was announced, and Sinopharm Group ranked 28th. In recent years, Sinopharm Group's revenue has repeatedly reached new highs, breaki
-
The pharmaceutical company's current personnel "earthquake": the president resigned, and the CEO of the subsidiary changed
Time of Update: 2022-09-21
Previously, the combination therapy of "amphavir monoclonal antibody" and "romizumab" of Tengsheng Bo Pharmaceuticals has received high attention, and since the drug was approved for listing at the end of last year, the company announced the commercialization of the product in China in July 2022, and the price is expected to be within 10,000 yuan.
-
Recently, the field of diabetes has ushered in a number of blockbuster new drugs
Time of Update: 2022-09-21
According to the China Drug Clinical Trial Registration and Information Publicity Platform, Eli Lilly has conducted five related clinical trials in China, in addition to the completed clinical trial of type 2 diabetes, there are three ongoing international multicenter Phase 3 clinical trials, the indications are obstructive sleep apnea and obesity, overweight/obesity, and reducing the compound outcomes of major adverse cardiovascular events in patients with type 2 diabetes mellitus with an increased risk of cardiovascular disease.
-
Chinese medicine is also welcoming good news, "going to sea" will be accelerated!
Time of Update: 2022-09-21
19 billion US dollars; the State Administration of Traditional Chinese Medicine has supported domestic TCM institutions to build 30 high-quality TCM overseas centers in the "Belt and Road" countries, and 56 TCM international cooperation bases in China, providing high-quality TCM services for the people of the "Belt and Road" countries.
-
Hainan: Tax, medical insurance and social security to achieve "one window through the office"
Time of Update: 2022-09-21
The relevant person in charge of the Hainan Provincial Taxation Bureau said that the "one-window general office" will effectively solve the "pain points" such as multi-window handling, repeated consultation, and long processing time of payers, marking a new level in the handling mode of social security management and payment business in Hainan Province.
-
Pharmaceutical companies are accelerating the "grab" of more than one billion yuan of heavy spiritual medicine market!
Time of Update: 2022-09-20
Recently, Fosun Pharma announced that the drug registration application of aripiprazole oral solution developed by its holding subsidiary Fosun Pharmaceutical Industry and its holding subsidiary Jinzhou Aohong Pharmaceutical has been accepted by the State Food and Drug Administration for the treatment of schizophrenia in adults and adolescents over 15 years old.
-
Sugar reduction and re-star Tirzepatide reported production in China, and sales are expected to exceed 10 billion US dollars in 2030
Time of Update: 2022-09-20
In the treatment of type 2 diabetes, in January this year, Eli Lilly announced that Tirzepatide had reached the primary and all key secondary endpoints in a 40-week SURPASS-AP clinical trial (comparing Tirzepatide with dose-titrated insulin glargine), significantly reducing glycosylated hemoglobin and body weight in patients with type 2 diabetes.
-
The key is to turn a profit from a profit and reduce the cost of raw materials such as Epimedium!
Time of Update: 2022-09-20
In terms of products, in the first half of 2022, in the company's main business, the operating income of traditional Chinese medicine was 340 million yuan, an increase of 50.
-
Notice on publicly soliciting opinions on the "Technical Guidelines for the Continuous Manufacture of Oral Solid Preparations of Chemical Drugs (Draft for Solicitation of Comments)"
Time of Update: 2022-09-20
Drug Evaluation Center of the State Drug Administration September 9, 2022 In order to encourage innovation and pharmaceutical modernization, help the implementation of the ICH Q13 guiding principles in China, and also to guide the research and development of enterprises and unify the evaluation scales, our center organized the drafting of the "Technical Guidelines for continuous manufacturing of oral solid preparations of chemical drugs (Draft for Comments)", which is now soliciting opinions from all sectors of society.
-
Shanghai pharmaceutical companies have accelerated the pace of "going to sea" and competed with foreign enterprises in a differentiated manner
Time of Update: 2022-09-20
In addition, the author has learned that Shanghai Jiyu Pharmaceutical, a subsidiary of Jimin Trust Group, has recently reached an exclusive licensing agreement with Roche and its Genentech, in which Shanghai Jiyu exclusively licenses the development and commercialization rights of the oral androgen receptor (AR) degrader JMKX002992 with independent intellectual property rights to Genentech in the world.
-
With the empowerment of science and technology, pharmaceutical companies are accelerating the exploration of new paths for digital transformation
Time of Update: 2022-09-20
In general, with the help of digital transformation, it can help pharmaceutical companies achieve refined operation, improve production efficiency, improve drug quality, and bring new growth breakthrough points to pharmaceutical companies.
-
The Chinese medicine industry will face a new round of reshuffle!
Time of Update: 2022-09-20
In the long run, the collection of proprietary Chinese medicines will help the standardized development of the industry, improve the quality standard system, and is expected to benefit enterprises with advantages in raw material supply, product quality and cost control, and continuous R&D investment.
-
Notice of Public Solicitation of Recommendations for the Implementation of the ICH Q3D(R2): Guiding Principles on Elemental Impurities and Chinese Edition
Time of Update: 2022-09-20
Q3D (R2) English version Drug Evaluation Center of the State Drug Administration September 8, 2022 In order to promote the smooth implementation of the newly revised ICH guidelines in China, our center has formulated the implementation recommendations of "Q3D (R2): Guiding Principles for Elemental Impurities" and organized the translation of Chinese version.
-
Heavy! The collection will be connected with the basic drug system, and the three types of drugs will not be included in the collection!
Time of Update: 2022-09-20
In the reply, the National Medical Insurance Bureau also revealed that in the procurement and assessment rules, the state will gradually improve the convergence of centralized procurement policies and the basic drug system, and promote medical institutions to give priority to the procurement and use of selected drugs on the basis of medication.
-
Beijing promotes the "going out" of traditional Chinese medicine to promote the coordinated development of industries such as pension and tourism
Time of Update: 2022-09-20
At the same time, relying on the Guang'anmen Hospital of the Chinese Academy of Chinese Medical Sciences, the "Beijing International Service Guidance and Evaluation Center for Traditional Chinese Medicine" was established as an industry policy research and management platform.
-
The National Alliance of Proprietary Chinese Medicines is about to procure, and there are a large number of drugs or price reductions
Time of Update: 2022-09-20
According to this trend, the industry expects that in the future, under the background of the continuous expansion of the collection of proprietary Chinese medicines, companies that lay out innovative chinese medicines and have cost and variety advantages will easily stand out and achieve price for volume.
